FDA Approved: DALIRESP — Supplemental Application (AstraZeneca Pharmaceuticals LP)

View source ↗

Summary

FDA approved a supplemental application for DALIRESP (roflumilast) from AstraZeneca Pharmaceuticals LP, updating labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Daliresp (roflumilast)

Snippet

SUPPL AP for DALIRESP (ROFLUMILAST)